Eversept Partners’s Lipocine LPCN Stock Holding History

Eversept Partners’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$755K	Hold	294,989	–	–	0.04%	110
2026 Q1	$2.36M	Buy	+294,989	New	+$2.57M	0.12%	84

Other funds holding LPCN

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

SFCM

Seven Fleet Capital Management Mountain View, California $606M AUM

Eversept Partners's LPCN Position: Q2 2026 in Review

Eversept Partners held its Lipocine (LPCN) position steady in Q2 2026 at 294,989 shares worth $755K. The position accounts for 0.04% of the portfolio, ranked #110.

Eversept Partners first reported a position in LPCN in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.36M in Q1 2026. 36 funds tracked by Wall St. Rank hold LPCN as of Q2 2026.

Eversept Partners held 294,989 shares of Lipocine worth $755K as of Q2 2026.
Eversept Partners left its Lipocine share count unchanged in Q2 2026.
Lipocine made up 0.04% of Eversept Partners's portfolio in Q2 2026, its #110 holding.
Eversept Partners first reported a position in Lipocine in Q1 2026 and has held it in 2 quarters since.
Eversept Partners's Lipocine position peaked at $2.36M in Q1 2026.
36 funds tracked by Wall St. Rank held Lipocine as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.